Elanco enters $1.3B canine dermatology market with Befrena launch

Elanco Animal Health (NYSE:ELAN) has announced the phased U.S. launch of Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody (mAb) injectable solution indicated for the treatment of canine allergic and atopic dermatitis.

The specialized biologic marks Elanco's entry into the high-margin, $1.3 billion domestic canine dermatology market, expanding its companion animal portfolio alongside its existing oral therapeutic lines.

Befrena is formulated to target and neutralize canine interleukin-31 (IL-31), a primary cytokine responsible for transmitting itch signals directly to the canine brain.

Clinical data demonstrates that the caninized antibody begins controlling pruritus within 24 hours of administration and delivers continuous symptomatic relief for six to eight weeks.

Administered strictly as an in-clinic subcutaneous injection under veterinary supervision, the therapy carries no structural restrictions regarding patient age or body weight, offering clinicians a flexible management profile for chronic skin allergies.

The treatment originally received commercial clearance from the U.S. Department of Agriculture (USDA) in December 2025.

With this rollout, Elanco becomes the only pet health organization to market two separate USDA-approved monoclonal antibody products, adding to Trutect, its therapeutic solution for canine parvovirus.

The initial commercial phase will deploy through an exclusive Early Experience Program, allowing select veterinary practices to integrate Befrena into active clinical protocols ahead of a broader, nationwide distribution push later this year.